Healthcare Leaders Income ETF (HHL.TO) Buy,…

Home

Daily Stock Opinions and Ratings

Healthcare Leaders Income ETF (HHL.TO)

7.06

-0.08 (1.12%)

as of Jun 30, 2026, 7:56:05 pm Market Open.

232 watching

Investor Insights

Jun 30, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

The Healthcare Leaders Income ETF (HHL-T) faces a challenging environment due to pressure on the US healthcare sector, notably from health insurance companies and policies affecting pharma costs. It maintains a diversified portfolio with roughly 20-23 large global healthcare names, focusing on pharmaceuticals (35%), healthcare equipment (25%), and biotech (14%). Experts recommend HHL for its balance of income generation and potential growth, especially when paired with ETFs like XHC for additional growth. Although the sector has been volatile and affected by political factors, some analysts believe the negativity surrounding it might be overdone, and recent inflows into the ETF suggest a rebound could be on the horizon. The demographic trends could further support a recovery as clarity emerges in the US healthcare landscape.

Consensus

Positive

Valuation

Fair Value

Similar

ABBV

TOP PICK

Healthcare sector lagging in the market, and is due for an increase in value. Very large companies with tailwind in aging population/demand for healthcare. Covered call strategy adds to yield. Good option for investors going forward.

PAST TOP PICK

(A Top Pick May 19/22, Up 6%)

It was strictly a yield play when interest rates were so low. He has only a small position. Growth in the ETF can be somewhat restrained by the covered call structure. It's a tradeoff between yield and growth. He's still bullish on the healthcare sector, the demographics are beautiful.

BUY

Very good for healthcare exposure.
Actively managed with good performance.
High dividend yield (~10%).
Good for long term investors.

DON'T BUY

Covered call. Equal weight basket of mainly 20 US healthcare names. Yield is 8.5%. MER of 99 bps, not as cheap as some of the others. He prefers, and owns, IXJ. IXJ is a basket of global healthcare names, with only a 40 bps MER.

BUY

It's a covered call US healthcare ETF. HC is a growth sector. HHL pays over an 8% dividend, so it's very attractive. The one-year chart shows little growth, so you buy this for the yield. Tailwind: the baby boomers are getting older, and there's a huge backlog of surgeries built up during Covid. Plus immigration. HC is definitely a growth area.

BUY

Good ETF for healthcare exposure (USA and international). Dividend does not qualify for Canadian divided tax credit. Look into tax treatment for each situation.

BUY

Allan Tong’s Discover Picks Among the caveats here is that HHL doesn't offer much growth. HHL is currently trading 30 cents above its 2022 low of $7.55, but its high is only $9.05. If you buy at current levels, add the dividend and subtract the MER, you're collecting a 13.5% return over a year. Not bad in these volatile times. Read 3 Best U.S. Healthcare ETFs for our full analysis.

Unspecified

It is a very large cap fund. Does some covered writing which gives away some upside. Whether you buy or not depends on your view of the health care space. It is 40% pharmaceuticals, 19% health care supplies, 15% health care services.

BUY

Believes healthcare sector is good for investors looking for yield (demand not going away). Not a growth story, but will provide stability.

BUY

Interesting company due to strong yield. Main issue is not as strong of growth as other stocks. Return has been strong regardless. Good for investors looking for income, but not growth.

BUY

Invests in healthcare issuers, a space he likes. Healthcare offers growth and defence and does well in late cycles and recessions. Pays enhanced dividends, too, with options totalling 8.7% dividends. The MER is around 1%, which is a little high. Covered calls do well in flat or down markets. Covered calls are also very tax efficient.

BUY ON WEAKNESS

HHL-T vs ZEB-T Canadian banks good long-term investment. European banks good as well. Canada doesn't have much exposure to healthcare stocks but they're going to be part of the future. HHL could be a way to play that. Have to think diversified. Good to make room for both of them in your portfolio.

TOP PICK

Likes the US healthcare industry, as all the aging baby boomers are entering high medical cost years. Covid delayed a lot of elective surgeries, creating a backlog. The yield on this ETF is extraordinary. He's trying this for his yield-oriented investors to make up for abysmal fixed income returns.

COMMENT

Hedged, unhedged, and USD versions. 20 large-cap US healthcare stocks, with a covered call strategy. Dividend comes from underlying securities plus covered calls. Because volatility is up so much, he's writing fewer calls to generate the same cashflow. He doesn't expect any changes to the distribution.

BUY

Would go for the defensive nature and dividend slant of the Harvest fund. It makes sense to be defensive. MER is a little higher but worth it for the active management. It has a longer term growth aspect to it as well.

Showing 16 to 30 of 89 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Healthcare Leaders Income ETF (HHL.TO)